SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
SER reported third quarter ended September 30, 2026 results. The price and volatility reaction is pending.
SERearnings

Earnings reactions, page 3

Serina Therapeutics, Inc. (SER) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss attributable to Serina common stockholders for the three months ended September 30, 2026 was $7.9 million, or $(0.31) per basic and diluted share, compared to $4.7 million, or $(0.45) per basic and diluted share for the same period in 2025.
  • Operating expenses for the three months ended September 30, 2026 were $8.0 million, compared to $6.4 million for the three months ended September 30, 2025.
  • Research and development expenses were $4.6 million for the three months ended September 30, 2026, compared to $3.6 million for the same period in 2025.
  • General and administrative expenses were $3.3 million for the three months ended September 30, 2026, compared to $2.7 million for the same period in 2025.
  • Cash and cash equivalents totaled $19.4 million as of September 30, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →